A page in the reference notebook
Bremelanotide
Also listed as: Vyleesi
Keep the record, its references, and your reading question together.
- Product status
- Approved product
- Evidence label
- Randomized evidence
- Body topics
- Sexual health
Status as of
Reference fields
Read the fields together.
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limitations
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
- Route and product context
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
A little room to think
One clearer reading question.
A dividing line can be a decision about how to describe observations. A break in a pattern would be something to establish from observations. Keep those origins separate. If a report assigns different labels on either side of a chosen boundary, the labels alone would not show that the underlying pattern changes abruptly there. Ask why the boundary was chosen and what supports any stronger claim about the pattern. This lets a grouping rule serve its intended purpose without turning a naming decision into a discovery about how something behaves.
Questions to keep nearby
- Was this boundary chosen as a rule or identified through an observed pattern?
- What supports a claim that the underlying pattern changes at that boundary?
- Could the grouping remain useful without implying an abrupt change in behavior?
Follow the record
Source list
- VYLEESI
NLM · Checked
- Kingsberg trials
PubMed · Checked